DDInter1042 DDInter1867
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Triflupromazine {u} (Compound) binds {v} (Gene) DRD1
Triflupromazine {u} (Compound) upregulates {v} (Gene) SLC2A6
Triflupromazine {u} (Compound) downregulates {v} (Gene) ZDHHC6
Triflupromazine (Compound) resembles Pipotiazine (Compound)
Triflupromazine (Compound) resembles Desipramine (Compound)
Triflupromazine (Compound) binds DRD1 (Gene)
Triflupromazine (Compound) upregulates SLC2A6 (Gene)
Triflupromazine (Compound) downregulates ZDHHC6 (Gene)